###### Strengths and limitations of this study

-   This is a multicenter, randomised, controlled, open-label phase 2 trial to evaluate the effect of a dexamethasone-based elixir on preventing chemotherapy-induced stomatitis.

-   The study aims is to generate evidence for the efficacy of a dexamethasone-based elixir mouthwash for preventing chemotherapy-induced stomatitis in patients with early breast cancer.

-   All women will receive a medical check-up by a dentist, and stomatitis will therefore be correctly diagnosed allowing the earlier identification of oral adverse events.

-   The incidence of stomatitis is determined from the patients' records and does not require an additional medical examination by the dentist.

-   No placebo drug is used in the control group.

Introduction {#s1}
============

Stomatitis can be painful, affect the patient's nutrition and quality of life, and have a significant economic impact.[@R1] Stomatitis occurs in approximately 20%--40% of patients receiving conventional chemotherapy, 80% of patients receiving high-dose chemotherapy as conditioning for haematopoietic stem cell transplantation, and in nearly all patients receiving head and neck radiation therapy.[@R1] Masuda *et al* reported a preventive effect of rebamipide in a randomised, multicenter phase 2 study of breast cancer patients with chemotherapy-induced stomatitis treated with 5-fluorouracil, epirubicin and cyclophosphamide, or with docetaxel and cyclophosphamide (TC),[@R2] and showed that about 60% of patients in both groups developed stomatitis.

The pathogenesis of stomatitis is multifactorial and complex. Lalla *et al* proposed that stomatitis occurred via five stages: (1) initiation of tissue injury, (2) upregulation of inflammation via generation of messenger signals, (3) signalling and amplification, (4) ulceration and inflammation and (5) healing.[@R3] This theory proposes that proinflammatory cytokines, produced mainly by macrophages, injure mucosal cells and activate molecular pathways that amplify mucosal injury. Subsequent inflammatory cell infiltrates are associated with mucosal ulceration, and excessive inflammation seems to exacerbate stomatitis.

Several studies have attempted to prevent chemotherapy-induced stomatitis. Palifermin reduced the duration and severity of stomatitis after intensive chemotherapy and radiotherapy in patients with haematological cancer.[@R4] Palifermin has therefore been approved by the US Food and Drug Administration and the European Medicines Agency for stomatitis patients with haematological malignancies. Oral cryotherapy prevented stomatitis in patients receiving bolus doses of 5-fluorouracil and haematopoietic stem cell transplantation.[@R5] Rebamipide is an internal-use mucosal protectant, and gargling with rebamipide has been reported to prevent stomatitis in patients with head and neck cancer who are receiving chemoradiotherapy.[@R6] However, recommendations for preventing chemotherapy-induced stomatitis in patients with breast cancer are lacking.

Oral care protocols are used to prevent stomatitis in all cancer treatment modalities.[@R1] Saforis (glutamine) is reportedly effective for preventing and treating stomatitis in patients with histopathologically confirmed breast cancer receiving anthracycline-based chemotherapy.[@R8] However, internal rebamipide showed no efficacy in preventing chemotherapy-induced stomatitis in breast cancer patients.[@R2] The Multinational Association of Supportive Care in Cancer (MASCC) MASCC/ISOO Mucositis Guidelines 2019 Update recommends photobiomodulation, parenteral or oral glutamine, and benzydamine mouthwash in patients undergoing haematopoietic stem cell transplantation and patients with head and neck cancer receiving radiotherapy with or without concomitant chemotherapy.[@R9] However, there is currently no recommendation for the prevention of stomatitis in breast cancer patients receiving chemotherapy without multi-agent combination oral care protocols.

Everolimus is an oral mammalian target of rapamycin (mTOR) inhibitor used to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Although the addition of an mTOR inhibitor to an aromatase inhibitor has been shown to prolong progression-free survival compared with an aromatase inhibitor alone, stomatitis is a frequent adverse effect of mTOR inhibitors.[@R13] The SWISH trial compared the prophylactic use of dexamethasone oral solution with historical controls from the BOLERO-2 trial, and showed that dexamethasone substantially reduced the incidence and severity of stomatitis in patients receiving an mTOR inhibitor by 40% (oral mucositis rate: 21% in the SWISH trial vs 61% in the BOLERO-2 trial).[@R14] The pathogenesis of stomatitis is therefore thought to involve excessive inflammation and can be treated by topical dexamethasone ointment. A prednisolone-containing mouthwash was also recently reported to reduce the incidence of stomatitis in breast cancer patients who developed grade 2--3 oral mucositis during the previous treatment cycle.[@R15] However, the study was not a randomised controlled trial and did not report the adverse events in detail.

The current randomised, controlled, phase 2 trial aims to assess the safety and efficacy of a dexamethasone-based elixir mouthwash for preventing chemotherapy-induced stomatitis in patients with early breast cancer.

Methods and analysis {#s2}
====================

Methods/design {#s2-1}
--------------

This is a multicenter, randomised, controlled, open-label phase 2 trial to evaluate the effect of a dexamethasone-based elixir on preventing chemotherapy-induced stomatitis. The patient flowchart is shown in [figure 1](#F1){ref-type="fig"}.

![Flowchart of participants.](bmjopen-2019-033446f01){#F1}

Eligibility criteria {#s2-2}
--------------------

Eligible patients are women with histologically confirmed invasive breast cancer, aged 20--80 years, with a performance status of 0--1, scheduled to receive epirubicin and cyclophosphamide or TC. Patients must have a normal oral mucosa at baseline. Patients with distant metastasis, prior treatment for breast cancer, unsuitable dentures, or who are pregnant or breast-feeding will be excluded.

Recruitment, setting and informed consent {#s2-3}
-----------------------------------------

Patients are being recruited from Nagasaki University, National Hospital Organization Nagasaki Medical Center and Japanese Red Cross Nagasaki Genbaku Hospital from December 2018. Patients are recruited when their chemotherapy regimen is explained. All women are screened again to determine their eligibility and are provided with a participant information sheet and asked to provide their written consent. A copy of the patient consent form is available as [online supplementary file 1](#SP1){ref-type="supplementary-material"}. Participants have the right to withdraw from the study at any time without having to give a reason.
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Randomisation {#s2-4}
-------------

The first researcher (SK) assigns women to the intervention or control groups using a centralised, remote computer-generated randomiser. Stratification factors are age and chemotherapy regimen. There will be an intervention-to-control ratio of 1:1. All data, including electronic and hardcopies, will be destroyed 5 years after the completion of the study.

Treatment and assessment schedule {#s2-5}
---------------------------------

The study period runs from day 1 of the first cycle of chemotherapy until day 1 of the fourth cycle of chemotherapy. Beginning on day 1 of the first cycle of chemotherapy, patients in the intervention group receive chemotherapy plus 10 mL of a dexamethasone-based elixir (0.1 mg/mL; swish for 2 min and spit, four times daily for 9 weeks). Other drugs and mouthwashes without dexamethasone will be allowed in both groups. The data-collection schedule is shown in [table 1](#T1){ref-type="table"}.

###### 

Time of data collection

  -------------------------------------------------------------------
                                   Collection time                
  -------------------------------- ----------------- ---- --- --- ---
  Consultation with a dentist\     ○                 ○    ○   ○   
  Check infection and stomatitis                                  

  Collect patient's report         --                --   ○   ○   ○

  Adverse events                   --                --   ○   ○   ○

  Number of bacteria (saliva)      ○                 ○    ○   ○   
  -------------------------------------------------------------------

In this study, all women in both groups will receive standard oral care and a medical examination by a dentist and dental hygienist. First, the dentist performs oral and dental screening, including a radiographical examination, and measures the number of bacteria in the saliva before chemotherapy. The dentist then checks for dental caries and stomatitis every 3 weeks on chemotherapy day. Patients also receive tooth-brushing instructions and professional mechanical tooth cleaning before and during chemotherapy. If an intraoral infection is detected in any patient in the intervention group, use of the dexamethasone-based elixir is stopped. Physicians check for any adverse events (both haematological and non-haematological toxicities) using the Common Terminology Criteria for Adverse Events (CTCAE) V.4.0. Patients will record the daily incidence of anorexia, stomatitis, food intake and dysgeusia, and the frequency of mouthwash use (only the intervention group) and of intraoral steroid ointment use (if present) ([figure 2](#F2){ref-type="fig"}). Because there is currently no standard intervention without oral care to prevent chemotherapy-induced stomatitis, all patients are allowed to use any medicines or supplements for preventing mucositis. As noted above, patients are required to record the use of intraoral steroid ointment for the treatment of stomatitis.

![Patients' records. Patients will record the daily incidences of anorexia, stomatitis, food intake and dysgeusia, and the frequency of mouthwash use (only the intervention group) and of intraoral steroid ointment use (if present).](bmjopen-2019-033446f02){#F2}

Trial endpoints {#s2-6}
---------------

### Primary endpoint {#s2-6-1}

The primary endpoint is the incidence of all-grade stomatitis according to patients' records after 9 weeks.

### Secondary endpoints {#s2-6-2}

1.  Incidence of stomatitis by grade in the intervention and control groups.

2.  Duration of stomatitis in the intervention and control groups.

3.  Completion rate of chemotherapy.

4.  Relative dose intensity of chemotherapy.

5.  Frequency of mouthwash use per day in the intervention group.

6.  Adverse events according to CTCAE V.4.0.

7.  Incidence of intraoral infections.

Safety monitoring {#s2-7}
-----------------

Any severe adverse events must be reported to the principal investigator. The principal investigator will then gather all information regarding these adverse events reported by the investigators from each institution and report them to the Clinical Research Review Board at Nagasaki University.

### Sample size {#s2-7-1}

On the basis of a previous study, we predicted the incidence of mucositis to be 50% in the control group and 30% in the intervention group.[@R2] We calculated that the trial would therefore need to include 54 patients in each group with a beta level of 0.1 and an alpha level of 0.2 (one-sided) using the χ^2^ test. Considering a 10% potential withdrawal rate, we therefore planned to enrol 120 patients (60 per group). The treatment-to-control ratio was 1:1.

Data management {#s2-8}
---------------

Data will be collected using case report forms. Data will be provided with a study code, and deidentified data will be used for the analyses. All hardcopies will be deidentified using a study code and stored securely in the hospital setting. All data will be discarded 5 years after completion of the study.

Statistical analyses {#s2-9}
--------------------

Analyses of the primary and secondary outcomes will be based on an intention-to-treat analysis, which will include withdrawal from the study. The patients' clinicopathological features will be compared between the intervention and control groups. Variables will be described as frequencies for categorical variables and median and interquartile ranges for quantitative variables. Associations between variables will be assessed using Fisher's exact test, with Wilcoxon's rank sum test used for quantitative variables. All statistical analyses will be performed using EZR software (Saitama Medical Center, Jichi Medical University, Japan).

Study status {#s2-10}
------------

Patients were first enrolled in December 2018. Fifty-five patients had been recruited as of April 2019, and recruitment is still ongoing.

Patient and public involvement statements {#s2-11}
-----------------------------------------

This research was carried out without patient or public involvement. Neither patients nor the public were involved in the development of the research question, study design or implementation of this trial. Patients will not be invited to develop patient-relevant outcomes or interpret the results, or to participate in the writing or editing of the final manuscript for readability or accuracy. Because the interventions in our study are routine procedures during clinical work, the burden of the intervention is assessed by the patients themselves.

Ethics and dissemination {#s3}
========================

All participants signed a written consent form. The findings will be disseminated through scientific and professional conferences, and in peer-reviewed journals.
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